{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-019961","form_type":"8-K","ticker":"AURX","cik":"0001091596","company_name":"Nuo Therapeutics, Inc.","filed_at":"2024-06-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.245562+00:00","generated_at":"2026-06-01T04:58:35.385249+00:00","sec_items":["4.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Nuo Therapeutics dismisses auditor Marcum, engages MaloneBailey; cites material weaknesses","bullets":["Effective June 7, 2024, dismissed Marcum LLP as independent auditor; engaged MaloneBailey, LLP for FY 2024.","Marcum's reports for FY2023 and FY2022 included going-concern explanatory paragraphs.","Identified material weaknesses: insufficient accounting staff and lack of effective internal control over financial reporting.","No disagreements with Marcum on accounting principles or audit scope prior to dismissal.","Marcum's letter to SEC agreeing with disclosures filed as Exhibit 16.1."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-019961","json":"https://secwatch.observer/filing/0001437749-24-019961.json","markdown":"https://secwatch.observer/filing/0001437749-24-019961.md","text":"https://secwatch.observer/filing/0001437749-24-019961.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1091596/000143774924019961/0001437749-24-019961-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1091596/000143774924019961/aurx20240606_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T04:58:35.385249+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}